Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Disruption of NSD1 in Head and Neck Cancer Promotes Favorable Chemotherapeutic Responses Linked to Hypomethylation.

Authors: Bui, Nam; Huang, Justin K; Bojorquez-Gomez, Ana; Licon, Katherine; Sanchez, Kyle S; Tang, Sean N; Beckett, Alex N; Wang, Tina; Zhang, Wei; Shen, John Paul; Kreisberg, Jason F; Ideker, Trey

Published In Mol Cancer Ther, (2018 07)

Abstract: Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) represents a distinct classification of cancer with worse expected outcomes. Of the 11 genes recurrently mutated in HNSCC, we identify a singular and substantial survival advantage for mutations in the gene encoding Nuclear Set Domain Containing Protein 1 (NSD1), a histone methyltransferase altered in approximately 10% of patients. This effect, a 55% decrease in risk of death in NSD1-mutated versus non-mutated patients, can be validated in an independent cohort. NSD1 alterations are strongly associated with widespread genome hypomethylation in the same tumors, to a degree not observed for any other mutated gene. To address whether NSD1 plays a causal role in these associations, we use CRISPR-Cas9 to disrupt NSD1 in HNSCC cell lines and find that this leads to substantial CpG hypomethylation and sensitivity to cisplatin, a standard chemotherapy in head and neck cancer, with a 40% to 50% decrease in the IC50 value. Such results are reinforced by a survey of 1,001 cancer cell lines, in which loss-of-function NSD1 mutations have an average 23% decrease in cisplatin IC50 value compared with cell lines with wild-type NSD1Significance: This study identifies a favorable subtype of HPV-negative HNSCC linked to NSD1 mutation, hypomethylation, and cisplatin sensitivity. Mol Cancer Ther; 17(7); 1585-94. ©2018 AACR.

PubMed ID: 29636367 Exiting the NIEHS site

MeSH Terms: CRISPR-Cas Systems/genetics; Carcinoma, Squamous Cell/drug therapy*; Carcinoma, Squamous Cell/genetics; Carcinoma, Squamous Cell/pathology; Cell Line, Tumor; Cisplatin/pharmacology; CpG Islands/drug effects; DNA Methylation/drug effects; DNA Methylation/genetics*; Drug Resistance, Neoplasm/genetics; Female; Gene Expression Regulation, Neoplastic/drug effects; Head and Neck Neoplasms/drug therapy*; Head and Neck Neoplasms/genetics; Head and Neck Neoplasms/pathology; Histone Methyltransferases; Humans; Intracellular Signaling Peptides and Proteins/genetics*; Male; Mutation/drug effects; Nuclear Proteins/genetics*; Papillomaviridae

to Top